CTOs on the Move

BioSig Technologies

www.biosigtech.com

 
BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.biosigtech.com
  • 8441 Wayzata Blvd Ste 240
    Minneapolis, MN USA 55426
  • Phone: 763.999.7330

Executives

Name Title Contact Details

Similar Companies

De Kroyft-Metz

De Kroyft-Metz is a Peoria, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SonarMed

SonarMed is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NeuroVision Imaging

NeuroVision is developing a noninvasive, quick, and inexpensive retinalimaging test for the early detection and diagnosis of Alzheimer`s disease.

TherOx

TherOx, Inc. (TherOx) is a private, venture-financed medical device company based in Irvine, California, dedicated to elevating the standard of care for treatment of heart attack patients. A heart attack is caused when an artery in the heart becomes blocked. Current treatment of heart attack is to reestablish blood flow in the blocked artery as quickly as possible. Typically, this is done with a combination of medication and a percutaneous coronary intervention (PCI) which may include the placement of a (intracoronary) stent. PCI successfully restores blood flow, but damage to the patient’s heart remains. Blood flow in the microvasculature downstream from the blockage is compromised, and critical heart muscle tissue is damaged – or infarcted – due to oxygen deprivation brought on by the heart attack. The intent of SuperSaturated Oxygen (SSO2) Therapy from TherOx is to salvage damaged heart tissue by placing a high concentration of oxygen (~760 – 1,000 mmHg, or 5 – 7 times normal levels) into the patient’s blood plasma and delivering it directly to the area impacted by the heart attack. SSO2 Therapy serves as a complement to PCI and stenting. Immediately following the interventional procedure, proprietary technology from TherOx mixes a pre-specified concentration of “SuperOxygenated” saline solution with the patient’s blood to produce SuperOxygenated blood. The SuperOxygenated blood is then delivered through a catheter to the oxygen deficient tissue. Company research has confirmed in clinical studies that SuperSaturated Oxygen Therapy has the potential to reverse ischemia and may resuscitate tissue that may otherwise die. SSO2 Therapy circulates the patient`s own blood via the existing arterial access site used for the stenting procedure. Thus, no new access site is required. The TherOx DownStream System and DownStream Cartridge bear the CE Mark but are not available for commercial distribution in the EU at this time.

DeRoyal Industries, Inc.

DeRoyal manufactures quality healthcare products worldwide. DeRoyal is behind everything from the number one orthopedic hospital brand to online tools that power the medical industry. We keep innovating because it's part of our heritage.